



## Mr. Pradip Shah appointed as Chairman of Pfizer Limited Board

*Mr. Pradip Shah succeeds Mr. R A Shah who stepped down as Chairman*

**MUMBAI, February 7, 2022:** At its meeting held on February 3, 2022, following the resignation of Mr. R A Shah, the Pfizer Limited Board of Directors appointed Mr. Pradip Shah as the Chairman of the Board of Pfizer Limited. Mr. Shah has been on the Board of Pfizer since December 1999 and has been guiding the Board and Management on various financial and strategic decisions.

Speaking about his appointment, **Mr. S. Sridhar, Managing Director, Pfizer Limited**, said, “Pfizer acknowledges and values *Mr. Pradip Shah’s contributions to the Board for many years as a financial expert, and I look forward to his continued advice and leadership. With his elevation as the Chairman of the Board, we will work closely with him on matters of strategic importance to Pfizer in India. I also wish to thank our outgoing Chairman, Mr. R A Shah, for his years of service, leadership, and counsel to the Board. He has guided the company to navigate in possibly every conceivable operating environment and has served as a force of continuity and stability in an Industry characterized by rapid changes.*”

Speaking about his new appointment, **Mr. Pradip Shah, Chairman of the Board**, said, “*I am honoured to have been entrusted this privilege and responsibility. Over the years, Pfizer Limited has proven to be a company that is committed to highest standards of corporate governance, accountability and transparency. I look forward to contributing to Pfizer’s vision for the future, with the support of my fellow Board members.*”

Mr. Pradip Shah is the ex-Managing Director of CRISIL, India’s first and the largest credit rating agency. Prior to founding CRISIL, Mr. Pradip Shah assisted in founding the Housing Development Finance Corporation (HDFC) in 1977. Mr. Shah has also served as a consultant to USAID, the World Bank, and the Asian Development Bank. Mr. Shah is a Director on the Board of several reputed companies and is also a member of various prestigious committees/commissions. Mr. Pradip Shah is presently the Chairman of Indasia Fund Advisors Pvt. Ltd. He holds an MBA from the Harvard Business School, is a Chartered Accountant and a Cost Accountant, and ranked first in India in the Chartered Accountancy Examination.

### **About Pfizer: Breakthroughs That Change Patients’ Lives**

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 170



years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at [www.pfizerindia.com](http://www.pfizerindia.com).

**Pfizer Disclaimer**

The information contained in this press release is only current as of its date. All actions and statements made herein or otherwise shall be subject to the applicable laws and regulations as amended from time to time. There is no representation that all information relating to the context has been taken care of in the press release and neither we undertake any obligation as to the regular updating of the information as a result of new information, future events or otherwise. We will accept no liability whatsoever for any loss arising directly or indirectly from the use of, reliance of any information contained in this press release or for any omission of the information. The information shall not be distributed or used by any person or entity in any jurisdiction or countries where such distribution or use would be contrary to the applicable laws or Regulations. It is advised that prior to acting upon this press release, independent consultation / advice may be obtained and necessary due diligence, investigation etc. may be done at your end.

**Media contact:**

Chikita Sobti

+ 91 98201 91347

[Chikita.sobti@pfizer.com](mailto:Chikita.sobti@pfizer.com)